Nipple aspirate fluid in relation to breast cancer

Breast

Volumn 8, Issue 4, 1999, Pages 169-174

  Phillips, H A ^a,b   Howard, G C W ^a,b   Miller, W R ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASPIRATION; BIOCHEMISTRY; BREAST CANCER; FEMALE; HUMAN; MOLECULAR BIOLOGY; NIPPLE; PRIORITY JOURNAL;

EID: 0032873175     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1054/brst.1999.0047     Document Type: Article

References (60)

1. Petrakis N L. Physiologic, biochemical, and cytologic aspects of nipple aspirate fluid. Breast Cancer Res Treat. 8:1986;7-19.
2. Wynder E L, Hill P. Prolactin, oestrogen and lipids in breast fluid. Lancet. II:1977;840-842.
3. Sartorius O W, Smith H S, Morris P, Benedict D, Friesen L. Cytologic Evaluation of Breast Fluid in the Detection of Breast Disease. J Natl Cancer Inst. 59:1977;1073-1080.
4. King E B, Chew K L, Petrakis N L, Ernster V L. Nipple Aspirate Cytology for the Study of Breast Cancer Precursors. J Natl Cancer Inst. 71:1983;1115-1121.
5. Dairkee S H, Hackett A J. Potential for cytologic breast fluid analysis in breast disease. Breast Cancer Res Treat. 8:1986;21-23.
6. Papanicolaou G N, Holmquist D G, Bader G M, Falk E A. Exfoliative cytology of the human mammary gland and its value in the diagnosis of cancer and other diseases of the breast. Cancer. 11:1958;377-409.
7. Gruenke L D, Craig J C, Petrakis N L, Lyon M B. Analysis of cholesterol, cholesterol-5,6-epoxides and cholestane-3 beta,5 alpha,6 beta-triol in nipple aspirates of human breast fluid by gas chromatography/mass spectrometry. Biomed Environ Mass Spectrom. 14:1987;335-358.
8. Petrakis N L, Mason L, Lee R, Sugimoto B, Pawson S, Cathpool F. Association of race, age menopausal status and cerumen type with breast fluid secretion in nonlactating women, as determined by nipple aspiration. J Natl Cancer Inst. 54:1975;829-834.
9. Wrensch M R, Petrakis N L, Gruenke L D. Factors associated with obtaining nipple aspirate fluid: Analysis of 1428 women and literature review. Breast Cancer Res Treat. 15:1990;39-51.
10. Miller W R, Elton R A, Loudon N. Oral contraceptive steroids and breast secretions. Br J Obstet Gynaecol. 96:1989;967-972.
11. King E B, Barrett D, Petrakis N L. Cellular composition of the nipple aspirate specimen of breast fluid. I. The benign cells. Am J Clin Pathol. 64:1975;728-738.
12. Groves A M, Carr M, Wadhera, Lennard T W J. An audit of cytology in the evaluation of nipple discharge. A retrospective study of 10 years experience. The Breast. 5:1996;96-99.
13. King E B, Kromhout L K, Chew K L. Analytic Studies of Foam Cells From Breast Cancer Precursors. Cytometry. 5:1984;124-130.
14. Buehring G C. Screening for breast atypias using exfoliative cytology. Cancer. 43:1979;1788-1799.
15. Page D L, Dupont W D, Rogers L W, Rados M S. Atypical hyperplastic lesions of the female breast: a long-term follow-up study. Cancer. 55:1985;2698-2708.
16. Petrakis N L, Ernster V L, King E B, Sacks S T. Epithelial dysplasia in nipple aspirates of breast fluid: association with family history and other breast cancer risk factors. J Natl Cancer Inst. 68:1982;9-13.
17. Petrakis N L, Wrensch M R, Ernster V L, Miike R, King E B, Goodson W H. Prognostic significance of atypical epithelial hyperplasia in nipple aspirates of breast fluid. Lancet. II:1987;505.
18. Wrensch M R, Petrakis N L, King E B. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol. 135:1992;130-141.
19. Wolfe J N, Albirt S, Belle S, Salane M. Breast parenchymal patterns and their relationship to risk for having or developing carcinoma. Radiol Clin North Am. 21:1983;127-135.
20. Lee M M, Petrakis N L, Wrensch M R, King E B, Miike R, Sickles E. Association of abnormal nipple aspirate cytology and mammographic pattern and density. Cancer Epidemiol Biomarkers Prev. 3:1994;33-36.
21. Rose D P. Hormones in breast fluid. Breast Cancer Res Treat. 8:1986;25-28.
22. Petrakis N L. Nipple aspirate fluid in epidemiologic studies of breast disease. Epidemiol Rev. 15:1993;188-195.
23. Sanchez L M, Vizoso F, Diez-Itza I, Lopez-Otin C. Identification of the major protein components in breast secretions from women with benign and malignant breast diseases. Cancer Res. 52:1992;95-100.
24. Petrakis N L, Doherty M, Lee R. Immunoglobulin levels in breast fluids from women with breast cancer. Clin Immunol Immunopathol. 7:1977;386-393.
25. Yap P L, Miller W R, Humeniuk, Pryde E A D, Mirtle C L, McClelland D B L. Milk protein concentrations in the mammary secretions of nonlactating women. J Reprod Immunol. 3:1981;49-58.
26. Hill P, Garbaczewski L, Wynder E L. Testosterone in breast fluid. Lancet. 1:1983;761.
27. Miller W R, Humeniuk V, Forrest A P. Factors affecting dehydroepiandrosterone sulfate levels in human breast secretions. Breast Cancer Res Treat. 1:1981;267-272.
28. Wynder E L, Hill P, Laakso K, Littner R, Kettunen K. Breast secretion in Finnish Women: a metabolic epidemiologic study. Cancer. 47:1981;1444-1450.
29. Ernster V L, Wrensch M R, Petrakis N L. Benign and malignant breast disease: initial results of serum and breast fluid analyses of endogenous estrogens. J Natl Cancer Inst. 79:1987;949-960.
30. Petrakis N L, Wrensch M R, Ernster V L. Influence of pregnancy and lactation on serum and breast fluid estrogen levels: implications for breast cancer risk. Int J Cancer. 40:1987;587-591.
31. Petrakis N L, Gruenke L D, Craig J C. Cholesterol and cholesterol epoxides in nipple aspirates of human breast fluids. Cancer Res. 41:1981;2563-2565.
32. Morin R J, Hu B, Peng S K, Sevanian A. Cholesterol oxides and carcinogenesis. J Clin Lab Anal. 5:1991;219-225.
33. Wrensch M R, Petrakis N L, Gruenke L D. Breast fluid cholesterol and cholesterol beta-epoxide concentrations in women with benign breast disease. Cancer Res. 49:1989;2168-2174.
34. Gruenke L D, Wrensch M R, Petrakis N L, Miike R, Ernster V L, Craig J C. Breast fluid cholesterol and cholesterol epoxides: relationship to breast cancer risk factors and other characteristics. Cancer Res. 47:1987;5483-5487.
35. Ing R, Petrakis N L, Ho J H. Unilateral breast-feeding and breast cancer. Lancet. II:1977;124-127.
36. Petrakis N L, Gruenke L D, Beelen T C, Castagnoli N, Craig J C. Nicotine in breast fluid of non-lactating women. Science. 199:1978;303-305.
37. Hill P, Wynder E L. Nicotine and cotinine in breast fluid. Cancer Lett. 6:1979;251-254.
38. Petrakis N L, Maack C A, Lee R E, Lyon M. Mutagenic activity of nipple aspirates of breast fluid. Cancer Res. 40:1980;188-189.
39. Scott W N, Miller W R. The mutagenic activity of human breast secretions. J Cancer Res Clin Oncol. 116:1990;499-502.
40. Diamandis E P, Yu H, Sutherland D J. Detection of prostate-specific antigen immunoreactivity in breast tumours. Breast Cancer Res Treat. 32:1994;301-310.
41. Yu H, Giai M, Diamandis E P. Prostate-specific antigen is a new favourable prognostic indicator for women with breast cancer. Cancer Res. 55:1995;2104-2110.
42. Sauter E R, Daly M, Linahan K. Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers Prev. 5:1996;967-970.
43. Kahana L, Bartal A H, Yechiell H, Guttman I, Sheinfeld M. Carcinoembryonic-like substance in breast fluid discharge and in milk of lactating women. Isr J Med Sci. 17:1981;1035-1040.
44. Dickson R B, Lippman M E. Cancer of the breast: molecular biology of breast cancer. Devita V T, Hellman S, Rosenberg S A. Cancer: principles and practice of oncology, 5th Edit. 1997;1541-1557 Lippincott-Raven, Philadelphia.
45. Rose D P. Hormones and growth factors in nipple aspirates from normal women and benign breast disease patients. Cancer Detect Prev. 16:1992;43-51.
46. Vogel V G. Early detection, epidemiology and prevention of breast cancer. Curr Opin Oncol. 4:1992;1017-1026.
47. Inaji H, Koyoma H, Motomura K. ErbB-2 Protein Levels in Nipple Discharge: Role in Diagnosis of Early Breast Cancer. Tumour Biol. 14:1993;271-278.
48. Motomura K, Koyama H, Noguchi S, Inaji H, Azuma C. Detection of c-erbB-2 gene amplification in nipple discharge by means of polymerase chain reaction. Breast Cancer Res Treat. 33:1994;89-92.
49. Hollstein M, Sidransky D, Vogelstein B, Harris C C. Mutations in Human Cancers. Science. 253:1991;49-53.
50. Phillips H A. The role of the p53 tumour suppressor gene in human breast cancer. Clin Oncol. 1999.
51. Koutselini H, Malliri A, Field J K, Spandidos D A. p53 expression in cytologic specimens from benign and malignant breast lesions. Anticancer Res. 11:1991;1415-1420.
52. Evans D G. Genetic markers of breast cancer. The Breast. 5:1996;374-376.
53. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science. 278:1997;1054-1058.
54. Jacobson D R, Mills N E. A highly sensitive assay for mutant ras genes and its application to the study of presentation and relapse genotypes in acute leukaemia. Oncogene. 9:1994;553-563.
55. Rhodes C H, Hosinger C, Porter D M, Sorenson G D. Analysis of the allele-specific PCR method for the detection of neoplastic disease. Diagn Mol Pathol. 6:1997;49-57.
56. Sauter E R, Ross E, Daly M. Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br J Cancer. 76:1997;494-501.
57. Chen T P, Dhingra K, Sahin A, Sneige N, Hortobagyi G, Aldaz C M. Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections. Breast Cancer Res Treat. 39:1996;177-185.
58. Andersen J A, Pallesen R M. Spread to the nipple and areola in carcinoma of the breast. Ann Surg. 189:1979;367-372.
59. Crook T, Crossland S, Crompton M R. p53 mutations in BRCA1-associated breast cancer. Lancet. 350:1997;638-639.
60. Gretarsdottir S, Thorlacius S, Valgarsdottir R. BRCA2 and p53 mutations in primary breast tumours in relation to genetic instability. Cancer Res. 58:1998;859-862.